Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood: An Observational Prospective Study.
Luka de Vos, Maria Jung, Ruth-Miriam Koerber, Emma G Bawden, Tobias AW Holderried, Jörn Dietrich, Friedrich Bootz, Peter Brossart, Glen Kristiansen, Dimo Dietrich
The Journal of Molecular Diagnostics | American Society for Investigative Pathology (ASIP) | Published : 2020
Patients with incurable cancer usually receive palliative treatment with significant toxicity and limited efficacy. Methylation analysis of circulating cell-free DNA (ccfDNA) in blood from cancer patients represents a promising approach for minimally invasive, real-time monitoring of treatment response. Short stature homeobox 2 (SHOX2) and septin 9 (SEPT9) methylation was analyzed in N = 8865 malignant and N = 746 normal adjacent tissues across 33 different malignancies from The Cancer Genome Atlas. Furthermore, we performed quantitative SHOX2 and SEPT9 ccfDNA methylation analysis in plasma obtained before and consecutively during treatment from prospectively enrolled N = 115 patients with v..View full abstract